Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of standard DA + gemtuzumab ozogamicin vs CPX-351 + gemtuzumab ozogamicin in pediatric de novo AML
2020-002762-13Phase 3
- Sponsor
- Children's Oncology Group
- Start
- Oct 2025
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of gemtuzumab ozogamicin, daunorubicin + cytarabine liposome, daunorubicin, cytarabine and gilteritinib in acute myeloid leukemia (AML) (2 arms), sponsored by Children's Oncology Group. Primary endpoint: Event-free survival (EFS).
02
Drugs
gemtuzumab ozogamicindaunorubicin + cytarabine liposomedaunorubicincytarabinegilteritinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2020-002762-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002762-13.